

GA²LEN ANNUAL CONFERENCE 2012
AGENDA



“Clinical Trials – the current situation and future chances in the limelight”

Working towards better definition of outcome parameters covering individual responses in sub-phenotypes

Monday, February 27th

SESSION 1 – chaired by Prof. Torsten Zuberbier and Prof. Sergio Bonini

- 10.00 – 10.05 Welcome and opening remarks
Introduction of GA²LEN and the aims of the conference
Prof. Torsten Zuberbier, GA²LEN Secretary General
- 10.05 – 10.25 The future role of GA²LEN and its new position in the EU
Prof. Bolesław Samoliński, GA²LEN Vice President
- 10.25 – 10.40 GA²LEN view – current status and unmet needs in allergy therapeutics and diagnostics
Prof. Sergio Bonini, Head of GA²LEN Clinical Trials group
- 10.40 – 10.55 The Manufacturers view – current situation and unmet needs.
The special role of allergen immunotherapy and allergen diagnostics
Lars Jacobsen – EAMG
- 10.55 – 11.15 *Coffee break*
- 11.15 – 11.45 **View of the EMA** – current status and unmet needs in allergy trials and clinical care
Prof. Guido Rasi – Executive Director of the European Medicines Agency
KEYNOTE SPEAKER
- 11.45 – 12.30 Panel discussion among the morning speakers
“Defining the unmet needs”
moderated by Prof. Sergio Bonini, Head of GA²LEN Clinical Trials group
- 12.30 – 13.15 *Lunch break / Press conference*

SESSION 2 – chaired by Prof. Marcus Maurer and Prof. Jean Bousquet

- 13.15 – 13.30 Examples of methodology and gaps in rare allergic diseases including rare sub-types of allergic diseases - “Schnitzler Syndrome”
Dr. Anna Simon, Radboud University Nijmegen Medical Centre
- 13.30 – 13.45 Fourth level treatment options in urticaria
Prof. Marcus Maurer

13.45 – 14.10 Hereditary angioedema and recurrent non-hereditary angioedema. How to devise trials for unpredictable recurrent diseases.
Prof. Bruce Zuraw – University of California, San Diego
KEYNOTE SPEAKER

Airways allergies

14.10 – 14.25 The patients view – current status and unmet needs in allergy therapeutics and diagnostics including ethics of placebo controlled trials
Frans Timmermans, Representative of EFA

14.25 – 14.40 Pediatric patients – Special needs
Prof. Kai-Håkon Carlsen

14.40 – 15.00 *Coffee break*

SESSION 3 – chaired by Prof. Bolesław Samoliński & Prof. Karin C. Lødrup

Filling the gaps – new possibilities in the design of clinical trials and statistical analysis

15.00 – 15.15 Novel ideas in design and statistical variation – comments from a GA²LEN collaborating CRO
Dirk Reitsma, PPD - GA²LEN industrial associate

15.15 – 15.40 Novel ideas and possibilities in using smart phone technologies in GA²LEN projects
Prof. Jean Bousquet, GA²LEN Vice President

15.40 – 17.00 Open discussion with today's **Keynote Speakers** and drafting of the cornerstones of the conference declaration
moderated by **Prof. Sergio Bonini & Prof. Jean Bousquet**

18.30 *Evening reception "Hörsaalruine"*
In the original lecture hall of Rudolph Virchow, one of the founding fathers of modern medicine. The ruins have eloquent room structure & historical, atmospheric charm.



Network of Excellence

Tuesday, February 28th

SESSION 4 – chaired by Dr. Karsten Weller & Dr. Angelos Neou

Unpublished results of GA²LEN projects and novel GA²LEN projects.

09.30 – 10.30 Results from GA²LENs Children - **PreDicta** and **MeDALL**

Nutritional components of the GA²LEN Programme

Dr Vanessa Garcia Larsen – Imperial College London – GA²LEN Partner

Skin Prick Test Follow-up study launch for March 2012

Dr. Karsten Weller - GA²LEN Integration Officer

10.30 – 11.00 *Coffee break / Q&A* with Dr. Karsten Weller about the Skin Prick Test Follow-Up Study